Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts

Journal of Molecular Medicine

Volumn 75, Issue 4, 1997, Pages 290-296

  Mackensen, Andreas ^a,b,c   Veelken, Hendrik ^c   Lahn, Michael ^c   Wittnebel, Sebastian ^c   Becker, Daniel ^c   Köhler, Gabriele ^c   Kulmburg, Peter ^c   Brennscheidt, Ulrich ^c   Rosenthal, Felicia ^c   Franke, Brigitte ^c   Mertelsmann, Roland ^c   Lindemann, Albrecht ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Freiburg University ^*

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

cytotoxic T lymphocytes; gene therapy; melanoma; tumor infiltrating lymphocytes; vaccination

Indexed keywords

INTERLEUKIN 2; TUMOR VACCINE;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; FEMALE; FIBROBLAST; GENE THERAPY; HUMAN CELL; IMMUNIZATION; MELANOMA; PHASE 1 CLINICAL TRIAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

AMINO ACID SEQUENCE; CANCER VACCINES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FIBROBLASTS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MIDDLE AGED; NEOPLASM TRANSPLANTATION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SKIN; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 8244261388     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050114     Document Type: Article

References (26)

1. Elwood JM, Koh HK (1994) Etiology, epidemiology, risk factors, and public health issues. Curr Opin Oncol 6:179-187
2. Kirkwood JM (1994) Systemic therapy of melanoma. Curr Opin Oncol 6:204-211
3. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676-1680
4. Mukherji B, Chakraborty NB (1995) Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 7:175-184
5. Boon T, Cerottini J-C, van den Eynde B, van der Bruggen P, van Pel A (1994) Tumor antigens recognized by T lymphocytes. Ann Rev Immunol 12:337-365
6. Mackensen A, Carcelain G, Viel S, Raynal M-C, Michalaki H, Triebel F, Bosq J, Hercend T (1994) Direct evidence to support the immunsurveillance concept in a human regressive melanoma. J Clin Invest 93:1397-1402
7. Coulie PG, Somville M, Lehmann F, Hainaut P, Brasseur F, Devos R, Boon T (1992) Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 50:289-297
8. Ramarathinam L, Castle M, Wu Y, Liu Y (1994) T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 179:1205-1214
9. Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschle M, Maass G, Payer E, Stingl G, Birnstiel ML (1995) Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. J Immunol 154:3406-3419
10. Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I, Sobol RE (1995) Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther 6:591-601
11. Veelken A, Mackensen A, Lahn M, Köhler G, Becker D, Franke B, Brennscheidt U, Kulmburg P, Rosenthal FM, Keller H, Hasse J, Schultze-Seemann W, Farthmann EH, Mertelsmann R, Lindemann A (1997) A phase I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer (in press)
12. Veelken H, Rosenthal FM, Schneller F, von Schilling C, Guettler IC, Herrmann F, Mertelsmann R, Lindemann A (1992) Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial. Biotech Ther 3:1-14
13. Falkson CI, Falkson G, Falkson HC (1991) Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403-1408
14. Berger DP, Fiebig HH, Navarro-Lückel IC, Hiddemann W, Licht T, Winterhalter BR, Leder GH, Löhr GW (1989) Development of cell lines from human xenografts growing subcutaneously in nude mice. Blut 59:321-325
15. 60Co gamma rays. Int J Cancer 35:275-280
16. Veelken H, Jesuiter H, Mackensen A, Kulmburg P, Schultze J, Rosenthal FM, Mertelsmann R, Lindemann A (1994) Primary fibroblasts from human adults as target cells for ex vivo transfection and gene therapy. Hum Gene Ther 5:1203-1210
17. Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, Hercend T (1993) Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 53:3569-3573
18. Mackensen A, Herbst B, Köhler G, Wolff-Vorbeck G, Rosenthal FM, Veelken H, Kulmburg P, Schaefer HE, Mertelsmann R, Lindemann A (1995) Delineation of the dendritic cell lineage by generating large numbers of Birbeck granule-positive Langerhans cells from human peripheral blood progenitor cells in vitro. Blood 86:2699-2707
19. Wei S, Charmley P, Robinson MA, Concannon P (1994) The extent of human germline T-cell receptor Vβ gene segment repertoire. Immunogenetics 40:27-36
20. Genevée C, Diu A, Nierat J, Caignard A, Dietrich P-Y, Ferradini L, Roman-Roman S, Triebel F, Hercend T (1992) An experimentally validated panel of subfamily-specific oligonucleotide primers (Vα1-w29/Vβ1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol 22:1261-1269
21. Ferradini L, Roman-Roman S, Azocar J, Michalaki H, Triebel F, Hercend T (1991) Studies on the human T cell receptor α/β variable region genes. II. Identification of four additional Vβ subfamilies. Eur J Immunol 21:935-942
22. Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180-199
23. Homes EC, Morton DL, Eilber FR, Golub SE, Sulit HL (1976) Immunotherapy in malignant melanoma. Natl Cancer Inst Monogr 44: 85-86
24. Barth A, Hoon DS, Foshag LJ, Nizze JA, Famatiga E, Okun E, Morton DL (1994) Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune respone. Cancer Res 54:3342-3345
25. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S (1988) Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48:5883-5893
26. Mukherji, B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J, Mauri F (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci 92:8078-8082